rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - Środki przeciwnowotworowe - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
erlotinib sandoz 100 mg tabletki powlekane
sandoz gmbh - erlotinibum - tabletki powlekane - 100 mg
erlotinib sandoz 150 mg tabletki powlekane
sandoz gmbh - erlotinibum - tabletki powlekane - 150 mg
erlotinib sandoz 25 mg tabletki powlekane
sandoz gmbh - erlotinibum - tabletki powlekane - 25 mg
erlotinib glenmark 25 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - erlotinibum - tabletki powlekane - 25 mg
erlotinib glenmark 100 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - erlotinibum - tabletki powlekane - 100 mg
erlotinib glenmark 150 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - erlotinibum - tabletki powlekane - 150 mg
erlotinib sun 25 mg tabletki powlekane
sun pharmaceutical industries europe b.v. - erlotinibum - tabletki powlekane - 25 mg
erlotinib sun 100 mg tabletki powlekane
sun pharmaceutical industries europe b.v. - erlotinibum - tabletki powlekane - 100 mg
erlotinib sun 150 mg tabletki powlekane
sun pharmaceutical industries europe b.v. - erlotinibum - tabletki powlekane - 150 mg